Description

Natera Is Quietly Raising Signatera Pricing Power — Could This Hidden Catalyst Supercharge Revenue Growth?

Natera Inc.’s recent financial results highlight significant achievements and challenges across its business segments. The company processed approximately 924,000 tests, including a record 225,000 minimal residual disease (MRD) tests in Q4 of 2025, marking a 56% increase compared to the previous year. This impressive volume contributed to a total revenue of $666 million for the quarter, reflecting a year-over-year growth rate of 40%. Natera’s gross margin reached 66.9%, bolstered by strong clinical performance and operational efficiencies, resulting in over $107 million in cash flow for 2025. Natera has projected revenue between $2.62 billion and $2.7 billion for 2026, alongside expected gross margins of 63% to 65%. The company plans to stabilize selling, general, and administrative (SG&A) expenses while strategically increasing research and development (R&D) investments, aiming for sustained cash flow generation in 2026. The company’s MRD product line, spearheaded by Signatera, continues to see robust adoption.